• Je něco špatně v tomto záznamu ?

Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium

P. Kovarikova, I. Pasakova-Vrbatova, A. Vavrova, J. Stariat, J. Klimes, T. Simunek,

. 2013 ; 76 () : 243-51.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc13031690

Dexrazoxane (DEX) is the only clinically used drug effective against anthracycline-induced cardiotoxicity and extravasation injury. However, the mechanism of its cardioprotective action still remains elusive. This paucity of comprehensive data is at least partially caused by the analytical difficulties associated with selective and sensitive simultaneous determination of the parent drug and its putative active metabolite ADR-925 in the relevant biological material. The aim of this study was to develop and validate the first LC-MS/MS method for simultaneous determination of DEX and ADR-925 in the isolated rat neonatal ventricular cardiomyocytes (NVCMs) and the cell culture medium. The analysis was performed on a Synergi Polar-RP column using the gradient profile of the mobile phase composed of 2mM ammonium formate and methanol. Electrospray ionization and ion trap mass analyzer were used as ionization and detection techniques, respectively. NVCMs were precipitated with methanol and the cell culture medium samples were diluted with the same solvent prior the LC-MS/MS analysis. The method was validated within the range of 4-80pmol/10(6) NVCMs and 7-70pmol/10(6) NVCMs for DEX and ADR-925, respectively, and at the concentrations of 8-100μM for both compounds in the culture cell medium. The practical applicability of this method was confirmed by the pilot analysis of NVCMs and the corresponding cell medium samples from relevant in vitro experiment. Hence, the LC-MS/MS method developed in this study represents a modern analytical tool suitable for investigation of DEX bioactivation inside the cardiomyocytes. In addition, the basic utility of the method for the analysis of DEX and ADR-925 in plasma samples was proved in a pilot experiment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031690
003      
CZ-PrNML
005      
20131007125803.0
007      
ta
008      
131002s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpba.2012.12.024 $2 doi
035    __
$a (PubMed)23339990
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kovarikova, Petra $u Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. petra.kovarikova@faf.cuni.cz
245    10
$a Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium / $c P. Kovarikova, I. Pasakova-Vrbatova, A. Vavrova, J. Stariat, J. Klimes, T. Simunek,
520    9_
$a Dexrazoxane (DEX) is the only clinically used drug effective against anthracycline-induced cardiotoxicity and extravasation injury. However, the mechanism of its cardioprotective action still remains elusive. This paucity of comprehensive data is at least partially caused by the analytical difficulties associated with selective and sensitive simultaneous determination of the parent drug and its putative active metabolite ADR-925 in the relevant biological material. The aim of this study was to develop and validate the first LC-MS/MS method for simultaneous determination of DEX and ADR-925 in the isolated rat neonatal ventricular cardiomyocytes (NVCMs) and the cell culture medium. The analysis was performed on a Synergi Polar-RP column using the gradient profile of the mobile phase composed of 2mM ammonium formate and methanol. Electrospray ionization and ion trap mass analyzer were used as ionization and detection techniques, respectively. NVCMs were precipitated with methanol and the cell culture medium samples were diluted with the same solvent prior the LC-MS/MS analysis. The method was validated within the range of 4-80pmol/10(6) NVCMs and 7-70pmol/10(6) NVCMs for DEX and ADR-925, respectively, and at the concentrations of 8-100μM for both compounds in the culture cell medium. The practical applicability of this method was confirmed by the pilot analysis of NVCMs and the corresponding cell medium samples from relevant in vitro experiment. Hence, the LC-MS/MS method developed in this study represents a modern analytical tool suitable for investigation of DEX bioactivation inside the cardiomyocytes. In addition, the basic utility of the method for the analysis of DEX and ADR-925 in plasma samples was proved in a pilot experiment.
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a kardiovaskulární látky $x farmakokinetika $7 D002317
650    _2
$a kultivované buňky $7 D002478
650    _2
$a chromatografie kapalinová $x metody $7 D002853
650    _2
$a ethylendiaminy $x farmakokinetika $7 D005029
650    _2
$a glycin $x analogy a deriváty $x farmakokinetika $7 D005998
650    _2
$a kardiomyocyty $x metabolismus $7 D032383
650    _2
$a pilotní projekty $7 D010865
650    _2
$a králíci $7 D011817
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a razoxan $x farmakokinetika $7 D011929
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $x metody $7 D021241
650    _2
$a tandemová hmotnostní spektrometrie $x metody $7 D053719
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a validační studie $7 D023361
700    1_
$a Pasakova-Vrbatova, Ivana $u -
700    1_
$a Vavrova, Anna $u -
700    1_
$a Stariat, Jan $u -
700    1_
$a Klimes, Jiri $u -
700    1_
$a Simunek, Tomas $u -
773    0_
$w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 76(2013), s. 243-51
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23339990 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20131007130323 $b ABA008
999    __
$a ok $b bmc $g 995777 $s 830135
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 76 $d 243-51 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
LZP    __
$a Pubmed-20131002

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...